Table 1.
Selected published clinical trials of CAR T-cell therapy.
| Authors | Target antigen | Costimulatory domain | Number of patients | Infused cell dose per kg | Conditioning | Patients with CR(%) | Patients with relapse (%) | Patients bridging to HSCT | Patients with CRS | Patients with NT | Patients with B-cell aplasia | OS rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grupp et al. (3) | CD19 | 4-1BB | 2 | (0.14-1.2) × 107 | None/Cy+Eto | 2(100%) | 1(50%) | 0 | 2(100%) Severe 50% | Unknown | 2(100%) | Unknown |
| Maude et al. (4) | CD19 | 4-1BB | 30 | (0.76-20.6) × 106 | Individualized | 27(90%) | 7(26%) | Unknown | 30(100%) Severe 27% | 13(43%) | 27(90%) | 78% (6m) |
| Lee et al. (5) | CD19 | CD28 | 20 | (1 or 3) × 106 | Cy+Flu | 14(70%) | 2(14%) | 10(50%) | 16(80%) Severe 30% | 6(30%) | None prolonged | 50% (12m) |
| Turtle et al. (6) | CD19 | 4-1BB | 30 | (0.2 or 2 or 20) × 106 | Cy+ Flu/Cy/Cy+Eto | 27(93%) | 9(33%) | 13(43%) | 25(83%) Severe 23% | 15(50%) | Unknown | Unknown |
| Gardner et al. (7) | CD19 | 4-1BB | 43 | (0.5-10) x 106 | Cy/Cy+Flu | 40(93%) | 18(45%) | 11(26%) | 40(93%) Severe 23% | 21(49%) | Unknown | 69.5% (12m) |
| Maude et al. (8) | CD19 | 4-1BB | 75 | (0.2-5.4) x 106 | Cy+Flu | 61(81%) | 22 (36%) | 8(11%) | 58(77%) Severe 47% | 30(40%) | 62(83%) | 76% (12m) |
| Park et al. (9) | CD19 | CD28 | 53 | (1 or 3) x 106 | Cy/Cy+Flu | 44(83%) | 25(57%) | 17(32%) | 45(85%) Severe 26% | 23(44%) | Unknown | 50% (12.9m) |
| Hay et al. (10) | CD19 | CD28/4-1BB | 53 | 2 x (105-106) | Cy/Cy+Flu | 45(85%) | 22(49%) | 18(34%) | 40(75%) Severe 19% | 12(23%) | Unknown | 50% (20m/5m)a |
| Frey et al. (11) | CD19 | 4-1BB | 35 | 5 × (107-108) | Individualized | 24(69%) | Unknown | 9(26%) | 33(94%) Severe 18% | 14(40%) | Unknown | 50% (19.1m) |
| Fry et al. (12) | CD22 | 4-1BB | 21 | (0.3 or 10 or 30) x 105 | Cy+Flu | 12(57%) | 8(66%) | Unknown | 16(76%) | 6(28%) | 12(57%) | Unknown |
| Pan et al. (13) | CD22 | 4-1BB | 34 | ≤4 x 106, ≤1 x 106 | Cy+Flu | 24(71%) | 5(21%) | 11(32%) | 31(91%) Severe 3% | 6(18%) | 19(56%) | Unknown |
| Shah et al. (14) | CD22 | 4-1BB | 58 | (0.3-3) x 106 | Cy+Flu | 40(73%) | 30(75%) | 14(25%) | Unknown | Unknown | Unknown | 38% (10m) |
CAR, chimeric antigen receptor; CR, complete remission; HSCT, hematopoietic stem cell transplantation; CRS, cytokine release syndrome; NT, neurotoxicity; OS, overall survival; Cy, cyclophosphamide; Eto, etoposide; Flu, fludarabine; m, months; aMRD-negative CR patients compared to those who did not(median OS: 20m vs 5m).